2023 CURE Formula Grant Program
December 19, 2022
This RFP invites Drexel University interdisciplinary program initiatives involving clinical, health services, and/or biomedical research. These funds will be used to promote hypothesis-driven research projects that will lead to high quality scholarship (i.e., publications), technology commercialization, submissions for extramural support and ultimately awards from the NIH, DOD, NSF, and other governmental agencies and foundations.
The maximum budget allowed for direct costs is $75,000 direct costs. The project period for the grant is for up to two years to allow completion of the Specific Aims - 7/1/2023 to 6/30/2025.
We anticipate that the PA Dept. of Health will release the official RFP announcement over the next few weeks. We are launching our internal competition in order to have Drexel's CURE projects ready for submission to the PA Dept. of Health by the Commonwealth's deadline.
ELIGIBILITY TO APPLY FOR FUNDS
Principal Investigators for the CURE grants must hold a full-time, primary faculty appointment (assistant professor or above) at Drexel University. Faculty members may submit only one CURE proposal as PI. Each proposal must have at least one co-investigator. Collaborations across Drexel’s schools or colleges are strongly encouraged. PIs with currently active CURE Formula Grant Projects are NOT eligible to apply as PI but may serve as Co-PI on a new project.
SUBMISSION AND DEADLINE
Completed CURE applications are due in the Drexel University Funding Portal no later than 5:00 PM on Tuesday, January 31, 2023. CURE Budgets must be approved in COEUS by January 31, 2023.
Applicants are required to submit the following documents in the Drexel University Funding Portal.
- CURE Formula Funding Application
- PHS 398 Budget Form
- Budget Justification
- IRB submission documents AND IRB Approval Letter (if applicable)
- IRB approval documents must have the exact same title as the CURE project
- Statement of Achievement from Prior Awardees (if applicable)
RESEARCH USING HUMAN SUBJECTS, HUMAN CELL OR HUMAN SPECIMENS
If the project requires the use of human subjects, human specimens/samples or human cells EVEN if they are de-identified, the PA-DOH requires you to have IRB approval. An IRB approval letter and IRB submission documents MUST be submitted with the application in the Drexel University Infoready Funding Portal.
Visit the HRP website for more information drexel.edu/research/compliance/human-research-protection-new/researchers/.
For CURE grant IRB related questions please contact: John Roberts, Executive Director, HRP, firstname.lastname@example.org or Janet Matthews, MSN, RN, Sr. Director, Research Program Development, CoM, email@example.com.
REVIEW PROCESS AND AWARD NOTIFICATION
The applications will be reviewed by the process used by standard NIH-type study sections. The panel will include faculty members from across the University, as determined by the scientific expertise required to conduct a fair and thorough review. Decisions for funding will be based upon scientific merit, as evaluated by the review panel, and programmatic need.
The RFP and application forms may be found on the Drexel University Funding Portal.
Contact Dr. Noreen Robertson at firstname.lastname@example.org with any questions related to grant requirements or the application process.